The scale of the issue is easy to underestimate. Recent global estimates of human population distribution suggest that a substantial share of humanity lives at moderate or high elevation, with large concentrations in the Andes, the Himalayan plateau and its surroundings, the highlands of East Africa, and the mountainous interior of Mexico and Central America. Cities such as Bogotá, Mexico City, Quito, La Paz, Kathmandu, and Denver all sit at altitudes where barometric pressure, and therefore the partial pressure of inspired oxygen, is significantly reduced compared with conditions at sea level. For the residents of these cities, sleep does not occur in the same physiological environment that most sleep medicine textbooks implicitly assume, and that mismatch has consequences for how breathing during sleep is measured, scored, and interpreted.

The core physics are straightforward but their downstream effects are not. As altitude increases, barometric pressure falls, and with it the partial pressure of oxygen in inspired air. The body responds with a suite of acclimatization mechanisms: ventilation rises, producing a mild respiratory alkalosis as carbon dioxide is washed out; oxygen saturation of hemoglobin drifts downward, particularly during sleep; and the chemoreflexes that govern breathing become more sensitive to changes in carbon dioxide and oxygen. During wakefulness these adjustments are usually well tolerated. During sleep, however, the normal withdrawal of the behavioral and cortical drive to breathe leaves chemical control in charge, and at altitude that chemical control system becomes unstable. The result is a characteristic pattern of periodic breathing, in which ventilation waxes and wanes in regular cycles, sometimes culminating in central apneas, pauses in breathing that originate not in blocked airways but in an over-responsive control loop.

This instability is often described in terms of loop gain, a control-systems measure of how strongly the respiratory system amplifies a small perturbation in blood gases. At altitude, the reduced inspired oxygen raises the gain of the peripheral chemoreflex, so a modest dip in oxygen saturation triggers a larger ventilatory response than it would at sea level. The resulting over-ventilation lowers carbon dioxide below the threshold needed to keep breathing going, breathing pauses follow, and the cycle repeats. Sleep itself amplifies the problem, because the carbon dioxide threshold for maintaining breathing rises during non-REM sleep, narrowing the window between apneic and hyperpneic thresholds. Classic laboratory work has shown that hypocapnic apneas and hypopneas develop readily during NREM sleep under hypoxic conditions, and more recent field studies have documented that these loop-gain effects differ between men and women, with sex-related differences in the propensity for high-altitude sleep-disordered breathing.

The clinical consequence is that a sleep study performed at 2,600 meters may look different from the same study performed at sea level, in the same person, on the same equipment. Oxygen saturation values that would be flagged as abnormal at low altitude may be unremarkable for a healthy resident of a high-altitude city, and thresholds used to score hypopneas or to calibrate oxygen therapy may need local adjustment. Studies of healthy adults sleeping at around 2,240 meters, for example, have documented breathing patterns and saturation levels that depart from low-altitude norms without indicating disease, while work in Bogotá at 2,640 meters has examined how apnea severity and oxygenation measures shift in adults living at that elevation. Conversely, patients with obstructive sleep apnea who live at altitude may show a distinct phenotype: research on high-altitude populations has described a predominance of REM-related obstructive events, a pattern with implications for how severity is graded and how treatment is titrated.

Altitude does not only add central events to the picture; it can also unmask or aggravate obstructive disease. The intermittent desaturation that accompanies upper airway narrowing is amplified when the baseline saturation is already lower, so the same degree of airway collapse produces deeper and longer oxygen dips at elevation. Some investigators have argued that mild chronic high-altitude exposure contributes to the comorbidity burden of obstructive sleep apnea-hypopnea syndrome, potentially worsening cardiovascular and metabolic risk. Comparative data from sleep clinics at different elevations in the mountain west of the United States have shown that altitude-associated central apnea can complicate both the diagnosis and the treatment of obstructive sleep apnea, because positive airway pressure therapy that works well at one elevation may behave differently at another, and residual central events may appear or disappear as patients move between altitudes.

That last point, the effect of moving between elevations, is where the newest evidence becomes particularly striking. A randomized crossover trial published in the same journal examined healthy residents of a moderate-altitude city who descended to low altitude for short periods, and found that even brief descent changed their sleep and breathing physiology. Meanwhile, an earlier study of patients with obstructive sleep apnea who traveled from moderate elevation to sea level documented changes in apnea severity with descent, and clinical experience in mountain regions has long noted that patients referred for sleep testing shortly after travel to a different altitude may yield results that do not reflect their usual condition. In practical terms, a sleep study is a snapshot not only of a patient but of the atmospheric conditions under which it was recorded, and the commentary argues that this context belongs in the interpretation.

What would it mean to take altitude seriously in sleep medicine? The commentary points toward several concrete adjustments. Reference values for oxygen saturation, desaturation indices, and normal breathing patterns during sleep should ideally be established or calibrated for the elevation at which testing occurs, rather than imported wholesale from low-altitude populations. Scoring conventions and severity thresholds might need altitude-specific interpretation, so that a given apnea-hypopnea index or saturation nadir is read in light of the local barometric environment. Clinicians should routinely record the altitude of the sleep laboratory or home testing device and consider it when reporting results, and should ask patients about recent travel between elevations before drawing conclusions from a single night. Researchers designing trials of sleep-disordered breathing, and reviewers comparing studies from different centers, face a parallel obligation: a multicenter study that pools data from Quito and Amsterdam without accounting for a 2,800-meter difference in testing conditions may be averaging away a real biological signal.

There is also a broader equity dimension that the commentary raises implicitly through its own vantage point. Sleep medicine guidelines, reference datasets, and device algorithms have historically been developed and validated largely at low altitude, in North American, European, and East Asian lowland populations. Yet a meaningful fraction of the world’s population lives at elevations where those assumptions are strained, and many of the countries most affected, including Colombia, Bolivia, Peru, Ecuador, Mexico, Nepal, and Ethiopia, have limited access to the specialized sleep centers where local normative data could be generated. Building altitude-aware sleep medicine is therefore not only a matter of physiological precision but of making diagnostics valid for the populations that actually use them. The author, who declares no competing interests and reports no specific funding for the commentary, frames the question as one that the field can no longer defer.

The takeaway for readers is deceptively simple: altitude matters, and it matters in both directions. For the lowlander who travels to the mountains, a few nights of periodic breathing and fragmented sleep are usually a normal acclimatization response, not a new disease, though they can complicate any testing done during the stay. For the high-altitude resident, the thinner air is home, and the sleep study that ignores it risks mislabeling normal physiology as pathology or, more dangerously, underestimating disease that is amplified by hypoxic stress. As home sleep apnea testing spreads to ever more diverse environments, the elevation printed on the report may deserve the same attention as the patient’s age, sex, and body mass index. The commentary’s message to the sleep medicine community is that the atmosphere is not background noise in a sleep study; it is part of the experiment.

Subject of Research: The influence of altitude on sleep-disordered breathing physiology and the interpretation of sleep studies

Article Title: Sleep studies: does the altitude matter?

Article References: Bazurto-Zapata, M. A. (2026). Sleep studies: does the altitude matter?. Journal of Clinical Sleep Medicine, 22(1), Article 142. https://doi.org/10.1007/s44470-026-00151-2

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00151-2

Keywords: sleep medicine, altitude, hypoxia, polysomnography, obstructive sleep apnea, central apnea, periodic breathing, loop gain, oxygen saturation, high-altitude populations, respiratory physiology, REM sleep